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ABSTRACT
Vancomycin (VCM) is indicated in combat against Gram-positive infections, but it is not considered a 
first-choice drug because of its adverse effects. It is believed that oxidative stress is the primary mechanism 
of endothelial injury and the consequent VCM toxicity, which varies from phlebitis to nephrotoxicity. 
Moreover, dose recommendations, dilution, rates and types of infusion are still controversial. The aim of 
this study was to determine the effect of different VCM dilutions in endothelial, liver and kidney injuries 
by biochemical parameters and histopathological analysis. Wistar rats were randomly divided into six 
groups and subjected to femoral vein cannulation for drug administration. Control groups received 0.9 
ml of saline and the others received VCM (10mg/Kg/day) at dilutions of 5.0 and 10.0 mg/mL for 3 and 7 
days. Homocysteine, hs-CRP, AST, ALT, GGT, urea, creatinine, lycopene, alpha-tocopherol, beta-carotene 
and retinol were analyzed. Kidney, liver and cannulated femoral vein fragments were collected.This study 
showed alterations in ALT which featured hepatotoxicity. However, drug dilutions were not able to show 
changes in other biochemical parameters. In contrast, kidney and endothelium pathological changes were 
observed. More studies are needed to characterize VCM induced kidney and endothelium toxicity and 
biochemical markers able to show such morphological modifications.
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INTRODUCTION
Vancomycin (VCM) is a complex tricyclic 
glycopeptide antibiotic produced by Streptococcus 
orientalis which has been used for approximately 
50 years (Gupta et al. 2011). This drug became 
even more relevant after the onset of methicillin-
resistant Staphylococcus aureus (MRSA) and 
penicillin-resistant pneumococci infections along 
An Acad Bras Cienc (2014) 86 (4)
1964 FELIPE R. BRUNIERA et al.
with other resistance mechanisms against beta-
lactam antibiotics (Dehority 2010).
VCM is poorly absorbed by the gastrointestinal 
tract, and thus its intravenous (I.V) administration 
is the usual choice most of the times (ANVISA 
internet site 2013). A unique I.V. dose of 1g in adults 
produces plasma concentrations of 15 to 30 µg/ml 
one hour after the infusion (Chambers 2010). The 
strains are considered sensitive with a minimum 
inhibitory concentration (MIC) < 4 µg/ml. In general 
it is effective against S. aureus, S. epidermidis, S. 
pyogenes, S. pneumoniae, streptococcus viridans, 
certain bacillus species, Actinomyces, Clostridium 
and Corynebacterium (Chambers 2010).
The mechanism of action of this drug 
consists in the inhibition of the bacterial cell wall 
biosynthesis (Gupta et al. 2011). The drug undergoes 
the redistribution phenomenon which makes the 
measurement of the peak plasma concentration 
difficult, and is influenced by the individual's age 
(ANVISA – internet site 2013). Only 5% of the drug 
is metabolized and its elimination is by renal excretion 
(ANVISA – internet site 2013, Jelassie et al. 2011). 
Around 90% of the administered drug is eliminated 
by glomerular filtration (Chambers 2010). Its plasma 
half-life varies between 4 and 11 hours, with an 
average time of 6 hours for patients with normal renal 
function (ANVISA internet site 2013).
Vancomycin chloride, basically used in hospitals, 
is administered by the intravenous route. It is supplied 
as sterile powder, and directions recommend a 
dilution of 2.5 to 5.0 mg/mL (ANVISA internet site 
2013, Jelassie et al. 2011). The drug has to be slowly 
infused during a period of at least 60 minutes with 
injection site rotation (Jelassie et al. 2011, Hicks and 
Hernandez 2011).
Adult dosage is 30 mg/Kg/day in 2 to 3 fractio-
nated doses or higher, if necessary. In children, the 
doses range according to age (ANVISA- internet 
site 2013, Chambers 2010). However, a consensus 
regarding pediatric dosages of Vancomycin has not 
been reached yet (Dehority 2010, Oudin et al. 2011).
VCM adverse effects are various: hypotension, 
tachycardia, phlebitis, nephrotoxicity, ototoxicity, 
hypersensibility reactions, chills, exanthema and 
fever. Nevertheless, it is prescribed to combat 
acute Gram-positive bacterial infections caused 
by microorganisms that are resistant to other 
antimicrobials and to patients who are allergic to 
penicillins and cephalosporins (Chambers 2010, 
Hicks and Hernandez 2011).
Some studies indicate that dosage recommen-
dations in published guidelines are frequently 
inadequate since they do not achieve therapeutic 
serum levels fast enough in patients with normal 
renal function (Nunn et al. 2011, Eiland et al. 2011). 
Other animal testing studies reveal oxidative stress 
induction given the increase of reactive oxygen 
species and the increase in the expression of 
complement expression genes after the use of VCM, 
having the onset of nephrotoxicity and phlebitis as 
an outcome (Oktem et al. 2005, Cetin et al. 2007, 
Dieterich et al. 2009). In a trial study conducted in 
2010, it was reported that the drug could directly 
affect the vascular tonus (Richter et al. 2010).
Recent trials suggest that the increase in 
number of cases of nephrotoxicity is associated 
with high doses of VCM, which are used to reach 
serum concentrations recommended by the main 
international guidelines in the event of treatment 
failure or resistance (Wong-Beringer et al. 2011).
The main risk factors related to the induction 
of nephrotoxicity by VCM are the use of high doses 
of the drug, long-term treatments, the use of VCM 
associated with other nephrotoxic substances, obesity 
and the patient’s overall condition (Gupta et al. 2011).
A literature review published in 2012 reported 
renal toxicity related to the use of vancomycin in 
10-20% and 30-40% of the cases when the drug 
was administered in conventional and high doses 
respectively. The conclusion is that the probable 
mechanism for such injury is associated with 
oxidative stress induction given the increase of 
reactive oxygen species (Elyasi et al. 2012).
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The aim of this study was to determine the effect 
of different VCM dilutions in endothelial, liver 
and kidney injuries in Wistar rats by biochemical 
(homocysteine, high sensitivity C-reactive 
protein, AST, ALT, GGT, urea and creatinine) and 
histopathological (cannulated femoral vein, liver 
and kidney) parameters.
MATERIALS AND METHODS
DESIGN AND ANIMALS
In this randomized controlled experimental trial, 
36 male albino Wistar rats (Rattus norvegicus) 
weighing around 300g were used. The animals were 
obtained from the animal facility of ABC Medical 
School. During the trial the rats were kept under a 
photoperiodic cycle of 12 h light per 12 h dark with 
controlled temperature, humidity, exhaust system 
(20 air changes per hour) and feeding. Proper animal 
handling and care was provided in compliance with 
the guidelines of the National Institute of Health 
in Brazil. The study was approved by the Local 
Animal Testing Ethics Committee under protocol 
number 004/2012.
TREATMENT
A total of 36 animals were randomly divided into 
6 groups, weighed and housed in separate cages 
with ad libitum access to food and filtered water. 
Next the rats were intraperitoneally anesthetized 
with ketamine (50 mg/kg) and intramuscularly 
with xylazine (10mg/kg) to be cannulated via 
femoral vein. The technique was performed by the 
insertion of a polyethylene tube (PE-3 connected 
to PE-1, Scientific Commodities) filled with a 
mixture of heparin 5000 IU and saline in the 
proportion of 1:100. The tube was inserted through 
the subcutaneous tissue of the animal with the aid 
of a trochanter, and it was externalized on the back 
of the rat between the shoulder blades. A stainless 
steel pin was placed at the tip of the tube (mandrel).
The 36 animals were treated as follows: 
infusion of VCM (10mg/kg/day) in dilutions of 
saline 5 mg/ml and 10 mg/ml for 3 days (groups 
3 and 4) and for 7 days (groups 5 and 6). Day-3 
and -7 control groups (groups 1 and 2 respectively) 
received 0.9 ml of saline per day. In the groups 
treated for 3 days, samples of blood and fragments 
from the kidneys, liver and femoral vein cannulated 
on the fourth day were collected from each animal. 
In the groups treated for 7 days, samples of blood 
and fragments from the kidneys, liver and femoral 
vein cannulated on the eighth day were collected 
from each animal.
A standardization of the procedure was 
established. During the days that followed the 
cannulation process, the tube was heparinized 
(0.1 ml) daily with a mixture of heparin 5000 IU 
and saline in the proportion 1:100. The following 
procedure was adopted for the administration 
of VCM or saline: 0.1 ml of water for injection 
(WFI) was used in order to wash the tube. Next, a 
solution of VCM or saline was slowly injected (T = 
3 minutes). Finally, after 10 minutes, the tube was 
heparinized (0.1 ml) and a stainless steel pin was 
inserted into its tip.
At the end of the experiment the animals 
were anesthetized with a mixture of xylazine (10 
mg/kg,ip) and ketamine (100 mg/kg,ip). Blood 
was collected from the aorta, placed into two dry 
tubes and properly refrigerated until the moment 
of the biochemical analysis. After the animals were 
sacrificed, fragments from the cannulated femoral 
vein, kidneys and liver were collected.
BIOCHEMICAL ANALYZES
Hs-CRP and homocysteine concentrations in plasma 
were quantified by competitive immunoassay 
technique through liquid phase boiling marked as 
ligand binding assay. Next, chemiluminescence 
measurement was performed with immobilized 
binding protein in vitro by means of an anti-ligand 
detection system. Plasma quantification of AST, 
ALT, GGT, urea and creatinine, was determined 
by the colorimetric enzymatic method using 
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spectrophotometric technique. Additionally, in order 
to evaluate the tissular response to the oxidative 
stress, serum levels of lycopene, alpha-tocopherol, 
beta-carotene and retinol were determined by 
the high-performance chromatographic method. 
All procedures were according to good clinical 
laboratory practices.
HISTOPATHOLOGICAL ANALYSIS
Fragments from liver, kidneys and cannulated 
femoral vein were fixed in a 10% buffered formal-
dehyde solution. The fixed samples were gradually 
dehydrated, paraffin-embedded and then sectioned 
at 5-mm thickness and stained for hematoxylin-
eosin (HE). The pictures were taken with a Fuji 
digital camera (Tokio, Japan) attached with a Nikon 
trinocular microscope model E200 (Tokio, Japan) 
which were submitted to two different pathologists 
for analysis so that the treated groups and control 
could be compared. All procedures followed good 
pathological anatomy practices.
STATISTICAL ANALYSIS
Statistical analysis was performed with the 
SPSS 17.0 software package (Microsoft, USA). 
All variables were analyzed descriptively. The 
Kolmogorov-Smirnov test was used to access the 
normality of distribution of data. Quantitative 
values were shown by measures of central 
tendency. The ANOVA test was used for analysis of 
variance. Whenever possible, the post-hoc Scheffé 
method was applied to adjust a significance level in 
multiple comparisons along with the Fisher’s test 
so that the association probability of the analyzed 
characteristics could be calculated. The significance 
level adopted for the analysis of results was p<0.05.
RESULTS
BIOCHEMICAL ANALYSIS
Table I shows the measurement results of ALT, AST, 
urea, creatinine and homocysteine. Values of AST 
(p=0.215), urea (p=0.421), creatinine (p=0.066) 
and homocysteine (p=0.117) did not differ among 
control and treated groups.
When the groups were compared, ALT value 
showed statistical difference (p=0.026). Hs-
CRP and GGT levels did not show alterations or 
statistical differences among the groups.
Table II highlights the relation of intervention 
and control groups to serum levels of antioxidant 
substances. Differences between dilutions and 
duration of treatment were not detected for the 
variables used for this purpose.
HISTOPATHOLOGICAL ANALYSIS
Figure 1 shows the kidney fragment from the group 
that received VCM 5 mg/ml for 7 days (group 5), 
and it highlights minor glomerular disturbance, cyto-
plasmic granulations in tubular cells and interstitial 
inflammatory infiltrate. Mild interstitial and glomerular 
capillary congestions could also be observed.
Figure 1 also reveals the kidney fragment 
from the group that received VCM 10 mg/ml for 
Group ALT (U/l) AST (U/l) Urea (mg/dl) Creatinine (mg/dl) Homocistein (μmol/l)
G1(control;3d) 43.7±8.5 87.4±16.7 49.0±6.9 0.5±0.1 9.3±2.7
G2(control;7d) 44.2±5.4 104.5±32.9 50.9±9.1 0.6±0.1 11.7±1.6
G3(5mg/ml;3d) 51.0±12.8 93.6±22.3 46.1±6.0 0.4±0.1 7.1±3.7
G4(10mg/ml;3d) 45.6±9.0 110.0±33.9 50.9±9.0 0.5±0.1 9.2±4.1
G5(5mg/ml;7d) 64.1±21.7 124.7±40.7 50.0±3.8 0.5±0.1 11.0±2.9
G6(10mg/ml;7d) 41.7±4.1 90.0±12.2 44.0±4.8 0.6±0.1 10.6±1.4
p Value p=0.026* p=0.215 p=0.421 p=0.066 p=0.117
TABLE I
Target Organs Injury Biomarkers.
ALT:alanine aminotransferase, AST:aspartate aminotransferase.* p<0.05.
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Figure 1 - A) Photomicrograph showing renal cortex from control group with 
preserved morphological structure along with glomerulus (*) and tubules with no 
alterations. In the detailed view, renal tubules. HE staining, 10μm. 10X magnified. 
B) Photomicrograph showing renal cortex from group 5, revealing a minor disturbance 
in the glomerular framework (*) and cytoplasmic granulation in tubular cells (arrow). 
HE staining, 10μm. 40X magnified. C) Photomicrograph showing renal cortex from 
group 5, revealing a minor disturbance in the glomerular framework (*) and interstitial 
inflammatory infiltrate. Presence of polymorph nuclear and mononuclear leukocytes 
(arrowhead). HE staining, 10μm. 10X magnified. D) Photomicrograph showing 
renal cortex from group 6, revealing acute lesion in these structures. Tubular cells 
show irregularities with granules in the cytoplasm (arrow). In the interstice, an acute 
capillary congestion, edema and large amount of inflammatory cells can be observed. 
HE staining, 10μm. 40X magnified. 889x558mm (72 x 72 DPI).
TABLE II
Analysis of Antioxidant Parameters among Groups.
Variables (μM) Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 p1
α-Tocopherol 19.7 +12.8 25.3 + 9.3 20 + 6.1 20.7 + 4.1 19.2 + 6.8 21 + 7.3 0.82
Retinol 2.3 + 0.5 2.2 + 0.3 2.5 + 0,3 2.4 + 0.4 2.5 + 0.4 2.2 + 0.4 0.58
Lycopene 0.8 +0.1 0.8 + 0.1 0.8 + 0.05 0.7 + 0.2 0.8 + 0.1 0.7 + 0.2 0.37
β-Carotene 0.6 + 0.2 0.5 + 0.1 0.5 + 0.1 0.5 + 0.1 0.6 + 0.2 0.6 + 0.2 0.29
1ANOVA test significance level. Whenever possible, the Scheffé method was applied to adjust a significance level in multiple 
comparisons along with the Fisher’s test so that the association probability of the analyzed characteristics could be calculated. N=36.
7 days (group 6). An acute structural injury in the 
renal cortex is evidenced in the figure. Tubular cells 
show irregularities with granules in the cytoplasm. 
Rupture of the Bowman’s capsule and glomerular 
disturbance can be observed along with an acute 
capillary congestion with edema and intense 
interstitial inflammatory infiltrate.
Figure 2 presents the cannulated femoral vein 
fragment from groups 5 and 6, highlighting intense 
inflammatory infiltrate with a large amount of 
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inflammatory cells, polymorphonuclear leukocytes 
or mononuclear cells and a mild edema. Plasmocytes 
and mastocytes were mostly evidenced.
The groups which were treated for 3 days 
(groups 3 and 4) showed minor alterations in the 
histopathological analysis, and the liver slides 
showed inconclusive results.
DISCUSSION
Our study managed to address the differences 
related to VCM dilutions and the duration of its 
administration. The animals used in the research 
did not present predisposing factors for endothelial, 
renal or hepatic injuries.
The results corresponding to endothelial injury 
and related to the levels of homocysteine, hs-CRP, 
lycopene, alpha-tocopherol, beta-carotene and retinol 
did not show any difference among the experimental 
groups, suggesting that duration, dosage and the 
different dilutions used in our experimental model 
are not able to alter such parameters. However, when 
the anatomopathological analysis was performed, 
we could observe a morphological alteration 
characterized by the presence of an inflammatory 
infiltrate associated with the intimal thickening, 
visualized in the vascular segment of the 7-day 
groups treated with different VCM dilutions.
Endothelial cells are important modulators of 
the normal homeostasis. One of the main effects 
of oxidative stress is a reduction in the nitric oxide 
biological activity and the resultant endothelial 
dysfunction (Alpers 2005, Costa et al. 2009). 
Figure 2 - A) Photomicrograph showing femoral vein sample (cannulated) from 
control group. In the area around the vein, inflammatory infiltrate can be observed. The 
presence of a darker area with multinucleated giant cells, where the cannula was inserted, 
is noted. HE staining, 10μm. 4X magnified. B) And C) Photomicrograph showing 
samples of femoral vein (cannulated) from groups 6 and 5 respectively. In the area 
around the vein, an intense inflammatory infiltrate with predominance of plasmocytes 
and mastocytes. The presence of a darker area with multinucleated giant cells, where 
the cannula was inserted, is noted. HE staining, 10μm. 4X and 10X magnified. D) 
Photomicrograph with higher magnification highlighting the inflammatory infiltrate 
from image B. HE staining, 10μm. 40X magnified. 889x571mm (72 x 72 DPI).
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Experimental animal trials associate the use of 
VCM with oxidative stress induction, like the onset 
of phlebitis and renal injury (Oktem et al. 2005, 
Cetin et al. 2007, Dieterich et al. 2009, Robibaro 
et al. 1998a, b).
Robibaro et al. also believe that although 
glycopeptide antibiotics are well tolerated, high 
concentrations may lead to endothelial dysfunction 
with noticeable cell damage, which may explain the 
phlebitis and pain in the injection area (Robibaro et 
al. 1998a, b).
In an experimental trial, Richter et al showed 
that the drug may also directly affect the vascular 
tonus (Richter et al. 2010). Roszell et al affirm 
that patients in use of VCM present higher 
peripheral I.V. complication rates when compared 
with the administration of other antibiotics (Roszell 
and Jones 2010). Despite the reports, signs of 
endothelial injury in the analyzed biochemical 
parameters could not be observed.
Concerning the prevalence of renal injury caused 
by VCM, it is known that there is a variation of 7-17% 
in patients that received the drug intravenously 
(Dieterich et al. 2009). Creatinine is a delayed marker 
and also has low sensitivity to acute kidney injury. 
Therefore, results based only on this parameter without 
histological evaluation compromise the diagnosis of 
renal injury due to the use of VCM (Kirsztajn 2007, 
Bostom et al. 2002, Shemesh et al. 1985, Vancomycin 
Toxicity, United States National Library of Medicine 
internet site 2013).
Our results also revealed that creatinine cannot 
evaluate renal injury; in other words, in this study, 
we could not establish statistical differences for 
this parameter. However, when it came to the 
anatomopathological exam, morphological alterations 
were detected and characterized by the presence of 
glomerular disturbance associated with inflammatory 
infiltrate and alterations in tubular cells.
Sodre et al. also affirm that no marker available 
today, including urea and creatinine, is completely 
effective to analyze renal function (Sodre et al. 
2007). Therefore, many studies first try to clarify 
the physiopathology, and some laboratories invest 
in the discovery of early identification forms of 
renal injuries secondary to drug therapy (Dieterich 
et al. 2009).
In general, the VCM-induced nephrotoxicity 
is the acute interstitial nephritis. The presence 
of diffuse edema and lympho-monocitary and 
eosinophilic interstitial infiltrate can be observed, 
a fact that corroborates the data found in group 
5 and, more acutely, in group 6 (Alpers 2005, 
Vancomycin Toxicity. United States National 
Library of Medicine internet site 2013, Kelly and 
Neilson 2012).
VCM is associated with minor and transitory 
increases in transaminases in serum in 1-5% of 
the cases (Liver Toxicity, United States National 
Library of Medicine internet site 2013). The drug 
is excreted by the kidneys, and only 5% of it is 
metabolized in the liver, a fact that could explain 
the absence of significant hepatic injury (Anvisa 
internet site 2013, Jelassie et al. 2011).
This assertion is consonant with the findings of 
Yoshida et al. The researchers did not observe any 
significant hepatic injury with the use of VCM in 
different doses (Yoshida et al. 2006). Chen et al., 
on the other hand, noticed an increase in incidence 
of hepatic injury with rise in ALT and AST levels 
related to VCM administration. However, most of 
the events ranged from mild to moderate intensity 
(Chen et al. 2011). In our study, the rats treated with 
different dilutions of vancomycin showed ALT 
alterations which characterized hepatotoxicity.
According to what was exposed above, it can 
be inferred that VCM dilution is a risk factor for 
hepatic and renal injuries, a fact that was observed 
due to an increase in ALT levels and in the 
histopathological analysis.
Besides dilution, the period of duration 
over which VCM is administered seems to play 
an important role in the development of such 
alterations. The endothelial stress model could not 
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show alterations according to dilution, dose and 
duration in relation to the biochemical parameters. 
However, there are signs of endothelial injury 
visualized in the histopathological analysis of the 
vascular segment, especially when administration 
period is longer. The proposed model could 
determine hepatic injury which was observed due 
to the increased levels of ALT. Morphological 
alterations could be seen in some cases; however, 
the proposed and commonly used markers do not 
help in the monitoring of vancomycin toxicity.
RESUMO
A Vancomicina (VCM) é indicada no combate à infecções 
por Gram-positivas, porém não é considerada um agente 
de primeira escolha por causa dos seus efeitos adversos. 
Acredita-se que o estresse oxidativo é o principal mecanismo 
responsável pela lesão endotelial e consequente toxicidade 
da VCM, que varia desde flebites à nefrotoxicidade. 
Ademais, as recomendações de doses, diluições, taxas e 
tipos de infusão ainda são controversos. O objetivo deste 
trabalho foi determinar o efeito de diferentes diluições 
de VCM na lesão endotelial, hepática e renal utilizando 
parâmetros bioquímicos e análise histopatológica. 
Ratos Wistar foram divididos aleatoriamente em seis 
grupos e submetidos à canulação da veia femoral para 
a administração de medicamentos. Os grupos controle 
receberam 0,9 ml de salina e os outros receberam VCM 
(10mg/Kg/dia) nas diluições de 5.0 e 10.0 mg/ml durante 
3 e 7 dias. Homocisteína, PCR-us, AST, ALT, GGT, 
ureia, creatinina, licopeno, alfa-tocoferol, beta-caroteno e 
retinol foram analisados. Fragmentos de rins, fígado e veia 
femoral canulada foram coletados. Este estudo mostrou 
alterações na ALT, caracterizando hepatotoxicidade. 
Entretanto, as diluições dos medicamentos não foram 
capazes de evidenciar alterações nos outros parâmetros 
bioquímicos. Por outro lado, alterações histopatológicas 
foram observadas nos rins e endotélio. Mais estudos 
são necessários para a caracterização do efeito da VCM 
quanto à toxicidade nos rins e endotélio e ainda na busca 
de marcadores bioquímicos capazes de evidenciar tais 
alterações morfológicas.
Palavras-chave: Vancomicina, lesão renal, estresse 
oxidativo, hepatotoxicidade, lesão endotelial.
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